Concise Drug Review: Pazopanib and Axitinib

Pazopanib and axitinib are both U.S. Food and Drug Administration approved ATP-competitive inhibitors of the vascular endothelial growth factor receptor. Pazopanib and axitinib have been shown to be effective and tolerable treatment options for patients with metastatic renal cell cancer and therefor...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: van Geel, Robin M.J.M., Beijnen, Jos H., Schellens, Jan H.M.
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2012
Témata:
New Drug Development and Clinical Pharmacology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3425526/
https://ncbi.nlm.nih.gov/pubmed/22733795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0055
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky